GlassScriptPhysician profile
John Joseph Frank
NPI 1003019563
$3,451.41
in general payments reported to CMS, 2019-2025
19 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $48.11 · 2021: $66.15 · 2022: $979 · 2023: $1,208 · 2024: $129 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196 · Travel and Lodging: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.37 |
| Travel and Lodging | $344.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,071.89 | 2019-2023 | Optis |
| Abiomed | $971.12 | 2019-2025 | Impella |
| Terumo Medical Corporation | $374.58 | 2019-2022 | |
| Medtronic Vascular, INC. | $220.51 | 2019 | |
| Amgen INC. | $127.37 | 2020-2025 | Repatha |
| Boston Scientific Corporation | $119.62 | 2019-2024 | Comet |
| Pfizer INC. | $97.31 | 2023-2025 | |
| Heartflow, INC. | $78.78 | 2022-2023 | Ffrct |
| Janssen Pharmaceuticals, INC | $59.06 | 2020-2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $56.36 | 2023 | Onpattro |
| Novartis Pharmaceuticals Corporation | $56.12 | 2024-2025 | |
| Medtronic, INC. | $50.56 | 2025 | Symplicity G3 |
| Philips North America LLC | $40.69 | 2019-2022 | |
| Esperion Therapeutics, INC. | $35.37 | 2022-2024 | Nexletol |
| Cook Medical LLC | $27.04 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.84 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.68 | 2021 | |
| Akcea Therapeutics, INC. | $15.78 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.73 | 2024 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.